Covington

Researchers are evaluating the safety and effectiveness of solbinsiran compared to a placebo in adults with severe hypertriglyceridemia, a condition involving very high triglyceride levels. This Phase 2, randomized, double-blind, placebo-controlled study aims to understand how solbinsiran affects triglycerides and other lipid measures. The study focuses on participants with fasting triglyceride levels of 500 mgdL or higher. Participants will be randomly assigned to receive either solbinsiran or a placebo through two subcutaneous injections. The study uses a parallel design, meaning participants receive only one of the two treatments. The trial will last at least 24 weeks, with assessments occurring from baseline through weeks 16 to 24 to measure changes in triglycerides and other lipids. During the study, participants will undergo evaluations of lipid levels including triglycerides, Angiopoietin-like-3, very-low-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol. Pharmacokinetic assessments will be done to measure the drug concentration over time. Safety and efficacy will be monitored throughout the trial, which is expected to complete in August 2027.

Researchers are evaluating the effect of muvalaplin in lowering cardiovascular risks among adults with elevated lipoproteina who either have atherosclerotic cardiovascular disease or are at risk of a first heart attack or stroke. This phase 3, randomized, double-blind study aims to investigate whether muvalaplin can reduce major adverse cardiovascular events compared to placebo in this high-risk population. Participants are randomly assigned to receive either muvalaplin or a placebo, both given orally. The study is designed with parallel groups and will last about 5.25 years, during which the occurrence of cardiovascular events and changes in lipoproteina levels will be closely monitored. Throughout the study, participants will undergo regular assessments including measurement of lipoproteina levels, monitoring of cardiovascular events such as heart attacks or strokes, and evaluation of healthcare resource use. The primary outcome is the time to first major adverse cardiac event, tracked from baseline until the study ends. Safety and pharmacokinetics of muvalaplin will also be evaluated during the trial period.